Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies

Wegovy® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1, 2025 - Novo Nordisk is focused on new ways to drive access and affordability for Wegovy®, the most…